Biased signalling in analgesic research and development

Alexandra Conibear, Chris P. Bailey, Eamonn Kelly

Research output: Contribution to journalReview articlepeer-review

Abstract

Ligand bias offers a novel means to improve the therapeutic profile of drugs. With regard to G protein-coupled receptors involved in analgesia, it could be advantageous to develop such drugs if the analgesic effect is mediated by a different cellular signalling pathway than the adverse effects associated with the drug. Whilst this has been explored over a number of years for the μ receptor, it remains unclear whether this approach offers significant benefit for the treatment of pain. Nevertheless, the development of biased ligands at other G protein-coupled receptors in the CNS does offer some promise for the development of novel analgesic drugs in the future. Here we summarise and discuss the recent evidence to support this.

Original languageEnglish
Article number102465
JournalCurrent Opinion in Pharmacology
Volume76
Early online date2 Jun 2024
DOIs
Publication statusE-pub ahead of print - 2 Jun 2024

Data Availability Statement

No data were used for the research described in the article.

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this